Angio-Seal® vs. Exo-Seal® for Closure of Arterial Puncture Sites

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by University Hospital Erlangen.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Harald Rittger, University Hospital Erlangen
ClinicalTrials.gov Identifier:
NCT01669382
First received: August 9, 2012
Last updated: August 20, 2012
Last verified: August 2012
  Purpose

Background:

Vascular closure devices (VCD) were developed to reduce access site bleedings, to improve patients´ comfort, and to accelerate ambulation after percutaneous coronary interventions (PCI). Despite higher complications rates in earlier studies, current data suggest similar complication rates or better outcomes after the use of VCD as compared to manual compression. ExoSeal (Cordis, Warren, NJ, USA) is a new, extravascular polyglykolacid (PGA) plug which occludes the puncture channel. Whether the use of this extravascular closure device is as effective as the more widely used plug/anchor mediated devices, has not been evaluated so far.

We performed a randomized, multicentre, single-blinded trial to compare the efficacy of the extravascular closure device ExoSeal in comparison to the collagen-based plug/anchor mediated AngioSeal system.

Methods:

304 patients receiving diagnostic angiography and/or PCI will be included in three centers. Exclusion criteria are contraindications for any VCD including 1. severe calcification of the access vessel, 2. severe peripheral artery disease, 3. puncture in the origin of the profound femoral artery, 3. non-femoral sheath insertion, 4. marked turtuosity of the femoral or iliac artery, 5. marked obesity or kachexia (BMI >40 or <20) and 6. patients on continuous medication with oral anticoagulants.

After the procedure, angiography of the accessed femoral artery is performed to rule out major risk factors for retroperitoneal hemorrhage, relevant peripheral stenoses of the common or the superficial femoral artery, or a location of the puncture site in the bifurcation of the profundal femoral artery.

We hypothesise, that the use of an extravascular closure device is not inferior to an anchor/plug mediated device regarding the occurrence of the following complications: bleeding, need for vascular surgery and device failure (primary endpoints). Secondary endpoints are the occurance of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device. Power was 80%, alpha 0.05. Bleeding will be defined according to the TIMI criteria. The study is actively enrolling patients, last inclusion will take place in September 2012.

Results and Conclusions:

Outcome data including the primary endpoint (bleeding, need for vascular surgery and device failure) will be presented for the first time.


Condition Intervention Phase
Acute Coronary Syndromes
Stable Angina Pectoris
Device: percutaneous coronary intervention
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: ACCESS: A Randomized, Multicenter, Single-Blinded Trial to Compare the Extrafemoral Closure Device Exo-Seal® and the Collagen-based Intravascular Device Angio-SealTM for Arterial Puncture Site Closure.

Resource links provided by NLM:


Further study details as provided by University Hospital Erlangen:

Primary Outcome Measures:
  • bleeding, need for vascular surgery and device failure [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
    bleeding, need for vascular surgery and device failure will be measured as primary endpoints within the first 24 hours.


Secondary Outcome Measures:
  • occurance of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device. [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
    Secondary endpoints are the occurance of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device.


Other Outcome Measures:
  • lab values [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
    red blood count after 24 hours


Estimated Enrollment: 304
Study Start Date: January 2012
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Exo Seal system
Percutaneous coronary intervention
Device: percutaneous coronary intervention
after the intervention patients are randomized to either Angio Seal or Exo Seal
Other Name: Exo Seal for closure of arterial puncture site
Active Comparator: AngioSeal system
percutaneous coronary intervention
Device: percutaneous coronary intervention
after the intervention patients are randomized to either Angio Seal or Exo Seal
Other Name: Exo Seal for closure of arterial puncture site

  Hide Detailed Description

Detailed Description:

Introduction In patients undergoing percutaneous coronary interventions (PCI) there is a rate of vascular complications of 0.8% to 5.5% (1). Albeit femoral sheaths sizes were reduced, arterial compression and long-term dressing after PCI still bear tremendous discomfort and groin pain for the patients. Furthermore, manual compression of the puncture site should be performed until activated clotting time is below 180 seconds (2).

Therefore, vascular closure devices (VCD) were developed to reduce access site bleedings, to improve patients´ comfort, and to accelerate ambulation after PCI.

The hemostatic puncture closure device Angio-Seal (St. Jude Medical, St. Paul, MS, USA) is a collagen based plug system with an anchor in the inner vessel wall. ExoSeal (Cordis, Warren, NJ, USA) is a extravascular polyglykolacid (PGA) plug, which closes the puncture site on an extravascular basis while occluding the puncture channel.

The aim of the current, randomized study is, to evaluate the effectiveness, safety and reliability of 2 different vascular closure devices.

Methods Consecutive patients with stable angina pectoris or silent ischemia with a positive stresstest will be randomized to either Angio-Seal or Exo-Seal, and included into the study after giving written informed consent.

Patients with contraindications for any VCD including 1. severe calcifications of the vessel site, 2. severe peripheral artery disease, 3. puncture in the origin of the femoral profundal artery, 3. non-femoral sheath insertion, 4. marked turtuosity of the femoral or iliac artery, and 5. marked obesity (BMI >40) or 6. kachexia (BMI <20)will be excluded from the study (3). As clinical exclusion criteria will serve: 1. any emergency intervention, 2. the use of Glycoprotein IIb/IIIa-antagonists during the intervention, and 3. patients on continuous medication with oral anticoagulants.

All patients will be loaded with either 300 mg or 600 mg of Clopidogrel or 60 mg of Prasugrel or 180 mg of Ticagrelor, followed by a maintenance dose of 75 mg or 150 mg of Clopidogrel or 5 mg or 10 mg of Prasugrel, or 90 mg of Ticagrelor prior to the intervention. After insertion of a 6 F sheath, unfractionated Heparin (UF) will be given until an activated clotting time-level (ACT) of 250 s will be achieved. The use of low -molecular weight Heparin (LMWH) according to the recommendations of the manufacturers for the purpose of anticoagulation during PCI is possible. The simultaneous use of UF and LMWH should be avoided.

Patients should receive PCI according to standard protocols (8). After the procedure, an angiography of the accessed femoral artery should be performed to rule out major risk factors for retroperitoneal hemorrhage, relevant peripheral stenoses of the common or the superficial femoral artery, or a location of the puncture site in the bifurcation of the profundal femoral artery (9). In addition, this method will identify patients with a non-femoral artery sheath insertion, for which the VCD utilization is not proven (10). Patients with strong tortuosity and/or calcification of the femoral arteries should also be excluded from the study (see exclusion criteria).

Towards the end of the intervention the ACT should be recorded again: Angio-Seal or ExoSeal may be implanted when ACT is < 300s. In patients randomized to manual compression with or without patch the sheath should be removed when the ACT is < 180s.

The use of protamine is left to the discretion of the operator. In patients randomized to either Angio-Seal or Exo-Seal the placement should be performed using the manufacturer´s recommended technique. The operator should be familiar with any device used in the study, and should have performed vascular closure with those devices at least fifty times.

After insertion of the VCD a circular groin dressing will be applied, and patients will be immobilized for 4 hours. After this, the arterial puncture site will be examined, and auscultation will be performed. If there is no relevant complication, ambulation will be initiated.

Pain during closure procedure or manual compression will be categorized according to the Borg scale, with minor pain defined as Borg < 5 and major pain as Borg ≥ 5 (13).

In patients with manual compression with or without patch, immobilization will last 8 hours. After this, inspection of the puncture site will be performed as mentioned above.

Anticoagulation either with unfractionated heparin or low molecular weight heparin will be restarted 6 hours after resolvement of the dressing. On the subsequent day, ultrasound and Doppler spectral analysis of the puncture site will be performed in all patients.

Complications will be assessed as being major or minor: Major complications are defined as need for vascular surgery, false aneurysm, AV-fistula, strong pain (Borg ≥ 5), hematoma ≥ 5 cm and major bleeding, whereas minor pain, hematoma < 5 cm and new wound dressing will be classified as minor complications. Bleeding will be identified as bleeding according to the TIMI criteria (12). TIMI major bleeding is defined as hemoglobin drop > 5 g/dl (with or without an identified site), TIMI "loss no site" as a haemoglobin drop > 4 g/dl but < 5 g/dl without an identified bleeding site, and TIMI minor bleeding as a hemoglobin drop > 3 g/dl but < 5 g/dl with bleeding from a known site or spontaneous gross hematuria.

Again pain will be categorized according to the Borg scale, with minor pain defined as Borg < 5 and major pain as Borg ≥ 5 (13).

Demographic and procedural data will be prospectively collected using a standardized procedural data sheet. This includes date and type of intervention, sheath size, procedure-related drug doses, and number of previous interventions. Major or minor complications, as well as the time of events will be recorded.

Statistical analysis Randomization will be performed Statistical analyses will be performed with SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Continuous data are expressed as mean values +/- standard deviation. For comparisons between paired data the students t-test will be used. A p-value < 0.05 will be regarded as statistically significant.

Risk-benefit ratio Achieving adequate hemostasis is crucial for the prevention of access site complications in patients undergoing PCI (3). The occurrence of vascular complications was an independent predictor of nonfatal myocardial infarction or death within one year after intervention (14), and has been associated with a significant increase in mortality (15). Advanced age, female gender, pre-existing vascular disease, emergent procedures, low body surface area (4, 8, 14), diabetes, hypertension, and cigarette smoking (15, 16) are also associated with an increased bleeding risk. Therefore adequate hemostasis still remains a challenge in interventional cardiology.

The recently introduced extravascular closure device ExoSeal theoretically offer some advantages. First, there is no foreign body, which is introduced into the artery, which, once misplaced potentially can lead to an occlusion of the artery, or to inflammation or allergic reactions. In addition to that , those devices might be used in patients with common contraindications for VCD´s like calicification, peripheral artery disease and turtuosity of the artery.

Since these devices are already introduced, but not evaluated sufficiently, there is need for a randomized comparison with an established system.

The risk-benefit ratio is well on the site of benefit, since all devices are regularly used in interventional cardiology and the estimated complication rate is in the range or even lower, than those, reported in the literature.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all patients who receive coronary angiography/intervention with an 6 F sheath

Exclusion Criteria:

  • severe calcification of the access vessel,
  • severe peripheral artery disease,
  • puncture in the origin of the profound femoral artery,
  • non-femoral sheath insertion,
  • marked turtuosity of the femoral or iliac artery,
  • marked obesity or kachexia (BMI >40 or <20)
  • patients on continuous medication with oral anticoagulants.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01669382

Locations
Germany
Klinikum Coburg Recruiting
Coburg, Germany, 96450
Contact: Johannes Brachmann, MD    0049-9651-8220 ext 6348    johannes.brachmann@klinikum-coburg.de   
Contact: Barbara Bluem, MD    0049-9561-8220 ext 33210    barbara.bluem@klinikum-coburg.de   
Principal Investigator: Johannes Brachmann, MD         
Universitätsklinikum Erlangen; Medizinische Klinik 2 Recruiting
Erlangen, Germany, 91054
Contact: Harald Rittger, MD    0049-9131-85 ext 45348    harald.rittger@uk-erlangen.de   
Contact: Johannes Ketterle, MD    0049-9131-85 ext 45341    johannes.ketterle@uk-erlangen.de   
Principal Investigator: Harald Rittger, MD         
Universitätsklinikum Gießen, Klinik für Kardiologie Recruiting
Gießen, Germany, 35392
Contact: Holger Nef, MD    0049-641-985 ext 42101    holger.nef@innere.med.uni-giessen.de   
Principal Investigator: Holger Nef, MD         
Sponsors and Collaborators
University Hospital Erlangen
Investigators
Principal Investigator: Harald Rittger, MD Universitätsklinikum Erlangen, Medizinische Klinik 2, Germany
  More Information

No publications provided

Responsible Party: Harald Rittger, Priv.-Doz. Dr. Harald Rittger, University Hospital Erlangen
ClinicalTrials.gov Identifier: NCT01669382     History of Changes
Other Study ID Numbers: Med2UKEr1/2012
Study First Received: August 9, 2012
Last Updated: August 20, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by University Hospital Erlangen:
AngioSeal, ExoSeal, PCI, puncture site

Additional relevant MeSH terms:
Acute Coronary Syndrome
Angina Pectoris
Angina, Stable
Cardiovascular Diseases
Chest Pain
Heart Diseases
Myocardial Ischemia
Pain
Signs and Symptoms
Vascular Diseases

ClinicalTrials.gov processed this record on October 23, 2014